THERAPEUTIC APPROACHES TO EPILEPTIC SEIZURES AND STATUS EPILEPTICUS IN DOGS
Keywords:
status epilepticus, dog, treatmentAbstract
Epilepsy is the most common neurological disorder in dogs. Status epilepticus (SE) is a serious and life-threatening neurological emergency in veterinary medicine, defined as sustained seizure activity or multiple consecutive seizures lasting longer than 30 minutes without complete recovery of consciousness in between. In some cases, SE becomes refractory to conventional treatment protocols and may result in severe outcomes, including death. This review aims to comprehensively evaluate both pharmacological and non-pharmacological treatment approaches used in the management of epileptic seizures and refractory status epilepticus in veterinary and human medicine. The objective is to provide current evidence-based information on effective seizure control, prevention of complications, and improvement of survival rates.
References
Charalambous, M., Muñana, K., Patterson, E. E., Platt, S. R., & Volk, H. A. (2024). ACVIM consensus statement on the management of status epilepticus and cluster seizures in dogs and cats. Journal of Veterinary Internal Medicine, 38(1), 19–40. https://doi.org/10.1111/jvim.16928
Shorvon, S., & Ferlisi, M. (2011). The treatment of super-refractory status epilepticus. Brain, 134(Pt 10), 2802–2818. https://doi.org/10.1093/brain/awr215
Charalambous, M., Bhatti, S. F. M., Volk, H. A., & Platt, S. (2022). Defining and overcoming the therapeutic obstacles in canine refractory status epilepticus. Veterinary Journal, 283–284, 105828. https://doi.org/10.1016/j.tvjl.2022.105828
Charalambous, M., Volk, H. A., Van Ham, L., & Bhatti, S. F. M. (2021). First-line management of canine status epilepticus at home and in hospital. BMC Veterinary Research, 17(1), 103. https://doi.org/10.1186/s12917-021-02805-0
Charalambous, M., Bhatti, S. F. M., Van Ham, L., Platt, S., Jeffery, N. D., Tipold, A., et al. (2017). Intranasal midazolam versus rectal diazepam for the management of canine status epilepticus. Journal of Veterinary Internal Medicine, 31(4), 1149–1158. https://doi.org/10.1111/jvim.14734
Kirmani, B. F., Au, K., Ayari, L., John, M., Shetty, P., & Delorenzo, R. J. (2021). Super-refractory status epilepticus. Aging and Disease, 12(4), 1097–1119. https://doi.org/10.14336/AD.2021.0302
Cheng, J. Y. (2016). Latency to treatment of status epilepticus is associated with mortality and functional status. Journal of the Neurological Sciences, 370, 290–295. https://doi.org/10.1016/j.jns.2016.10.004
Luca, J., McCarthy, S., Parmentier, T., Hazenfratz, M., Zur Linden, A., Gaitero, L., & James, F. M. K. (2023). Survey of electroencephalography usage and techniques for dogs. Frontiers in Veterinary Science, 10, 1198134. https://doi.org/10.3389/fvets.2023.1198134
Rogawski, M. A., Loya, C. M., Reddy, K., Zolkowska, D., & Lossin, C. (2013). Neuroactive steroids in status epilepticus. Epilepsia, 54(Suppl 6), 93–98. https://doi.org/10.1111/epi.12289
Charalambous, M., Volk, H. A., Tipold, A., Erath, J., Huenerfauth, E., Gallucci, A., et al. (2019). Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs. Journal of Veterinary Internal Medicine, 33(6), 2709–2717. https://doi.org/10.1111/jvim.15627
Yıldırım, K. A., & Sünter, G. (2016). Refractory status epilepticus. Türkiye Klinikleri Journal of Neurology, 9(3), 102–107.
Naeser, J., Lichtenberger, M., Mariani, C. L., Thamm, D. H. M., & Kirby, R. (2004). Clinical comparison of lorazepam versus diazepam in dogs.
Blades Golubovic, S., & Rossmeisl, J. H., Jr. (2017). Status epilepticus in dogs and cats, part 2: Treatment, monitoring, and prognosis. Journal of Veterinary Emergency and Critical Care, 27(3), 288–300. https://doi.org/10.1111/vec.12604
Patterson, E. E., Leppik, I. E., Coles, L. D., Podell, M., Vite, C. H., Bush, W., & Cloyd, J. C. (2015). Fosphenytoin in canine status epilepticus. Epilepsia, 56(6), 882–887. https://doi.org/10.1111/epi.12994
Popławska, M., Borowicz, K. K., & Czuczwar, S. J. (2015). Fosphenytoin safety and efficacy. Expert Review of Neurotherapeutics, 15(9), 983–992. https://doi.org/10.1586/14737175.2015.1074523
Can, P., Pirpanahi, E., & Beşaltı, Ö. (2018). Neurological emergencies. In E. Elma (Ed.), Emergency applications in small animal practice (pp. 53–59). Türkiye Klinikleri.
Gioeni, D., Di Cesare, F., D’Urso, E. S., Rabbogliatti, V., & Ravasio, G. (2020). Ketamine–dexmedetomidine and hypothermia in super-refractory status epilepticus in dogs. Journal of Veterinary Emergency and Critical Care, 30(4), 455–460. https://doi.org/10.1111/vec.12956
Çelebi, H., Candan, N., & Günaydın, D. (2007). Propofol infusion syndrome. Anestezi Dergisi, 15(2), 73–80.
Nowakowska, M., Üçal, M., Charalambous, M., Bhatti, S. F. M., Denison, T., Meller, S., et al. (2022). Neurostimulation in canine drug-resistant epilepsy. Frontiers in Veterinary Science, 9, 889561. https://doi.org/10.3389/fvets.2022.889561
Vuu, I., Patterson, E. E., Wu, C. Y., Zolkowska, D., Leppik, I. E., Rogawski, M. A., et al. (2022). Allopregnanolone for status epilepticus in dogs. Journal of Pharmacology and Experimental Therapeutics, 380(2), 104–113. https://doi.org/10.1124/jpet.121.000736
Bruun, D. A., Ma, B., Chen, Y. J., Wu, C. Y., Aleman, M., Zolkowska, D., Smiley-Jewell, S. M., Rogawski, M. A., & Lein, P. J. (2023). Tolerability and pharmacokinetics of intravenous allopregnanolone with and without midazolam pretreatment in two healthy dogs. Epilepsia Open, 8(2), 666–672. https://doi.org/10.1002/epi4.12723
Tipold, A., Keefe, T. J., Löscher, W., Rundfeldt, C., & de Vries, F. (2015). Imepitoin versus phenobarbital. Journal of Veterinary Pharmacology and Therapeutics, 38(2), 160–168. https://doi.org/10.1111/jvp.12151
Bhatti, S. F. M., De Risio, L., Muñana, K., Penderis, J., Stein, V. M., Tipold, A., Berendt, M., Farquhar, R. G., Fischer, A., Long, S., Löscher, W., Mandigers, P. J., Matiasek, K., Pakozdy, A., Patterson, E. E., Platt, S., Podell, M., Potschka, H., Rusbridge, C., & Volk, H. A. (2015). International veterinary epilepsy task force consensus proposal: Medical treatment of canine epilepsy in Europe. BMC Veterinary Research, 11, 176. https://doi.org/10.1186/s12917-015-0464-z
Vuu, I., Coles, L. D., Maglalang, P., Leppik, I. E., Worrell, G., Crepeau, D., et al. (2016). Intravenous topiramate in dogs. Frontiers in Veterinary Science, 3, 107. https://doi.org/10.3389/fvets.2016.00107
Dewey, C. W., Rishniw, M., & Sakovitch, K. (2022). Felbamate as an oral add-on therapy in six dogs. Open Veterinary Journal, 12(4), 445–450. https://doi.org/10.5455/OVJ.2022.v12.i4.5
Pellock, J. M., Faught, E., Leppik, I. E., Shinnar, S., & Zupanc, M. L. (2006). Felbamate: Consensus of experience. Epilepsy Research, 71(2–3), 89–101. https://doi.org/10.1016/j.eplepsyres.2006.06.020
Ruehlmann, D., Podell, M., & March, P. (2001). Felbamate for partial seizures in dogs. Journal of Small Animal Practice, 42(8), 403–408. https://doi.org/10.1111/j.1748-5827.2001.tb02490.x
Sanders, S. (2015). Seizures in dogs and cats. Spi Publisher Services.
Leppik, I. E. (2004). Zonisamide: Chemistry and pharmacokinetics. Seizure, 13(Suppl 1), S5–S9. https://doi.org/10.1016/j.seizure.2004.04.016
Biton, V. (2007). Clinical pharmacology and mechanism of action of zonisamide. Clinical Neuropharmacology, 30(4), 230–240. https://doi.org/10.1097/wnf.0b013e3180413d7d
Dewey, C. W., Guiliano, R., Booth, D. M., et al. (2004). Zonisamide therapy for refractory idiopathic epilepsy in dogs. Journal of the American Animal Hospital Association, 40(4), 285–291. https://doi.org/10.5326/0400285
Evans, R. H., & Hill, R. G. (1978). GABA-mimetic action of etomidate. Experientia, 34(10), 1325–1327. https://doi.org/10.1007/BF01981448
Doty, P., Hebert, D., Mathy, F. X., Byrnes, W., Zackheim, J., & Simontacchi, K. (2013). Development of lacosamide for partial-onset seizures. Annals of the New York Academy of Sciences, 1291, 56–68. https://doi.org/10.1111/nyas.12213
Dewey, C. W., Cerda-Gonzalez, S., Levine, J. M., Badgley, B. L., Ducoté, J. M., Silver, G. M., et al. (2009). Pregabalin as an adjunct therapy in dogs with suspected idiopathic epilepsy. Journal of the American Veterinary Medical Association, 235(12), 1442–1449. https://doi.org/10.2460/javma.235.12.1442
Yang, J., & Phi, J. H. (2019). The present and future of vagus nerve stimulation. Journal of Korean Neurosurgical Society, 62(3), 344–352. https://doi.org/10.3340/jkns.2019.0037
Muñana, K. R., Vitek, S. M., Tarver, W. B., Saito, M., Skeen, T. M., Sharp, N. J., et al. (2002). Use of vagal nerve stimulation in dogs. Journal of the American Veterinary Medical Association, 221(7), 977–983. https://doi.org/10.2460/javma.2002.221.977
Martlé, V., Peremans, K., Raedt, R., Vermeire, S., Vonck, K., Boon, P., Van Ham, L., Tshamala, M., et al. (2014). Brain perfusion changes during vagus nerve stimulation in dogs. Epilepsy Research, 108(4), 616–622. https://doi.org/10.1016/j.eplepsyres.2014.02.004
Martlé, V., Van Ham, L. M., Boon, P., Caemaert, J., Tshamala, M., Vonck, K., et al. (2016). Vagus nerve stimulator placement in dogs. Veterinary Surgery, 45(1), 71–78. https://doi.org/10.1111/vsu.12427
Speciale, J., & Stahlbrodt, J. E. (1999). Ocular compression-induced vagal stimulation in dogs. Journal of the American Veterinary Medical Association, 214(5), 663–665.
Zamora, M., Meller, S., Kajin, F., Sermon, J. J., Toth, R., Benjaber, M., et al. (2021). Digital chronotherapy in canine status epilepticus. Frontiers in Neuroscience, 15, 734265. https://doi.org/10.3389/fnins.2021.734265
Long, S., Frey, S., Freestone, D. R., LeChevoir, M., Stypulkowski, P., Giftakis, J., & Cook, M. (2014). Placement of deep brain electrodes in the dog. Journal of Veterinary Internal Medicine, 28(1), 189–197. https://doi.org/10.1111/jvim.12235
Poma, R., Parent, J. M., Monteith, G., & Stiebert, V. M. (2005). Transcranial magnetic stimulation in epileptic dogs. Epilepsia, 46, 333–334.
Sun, W., Mao, W., Meng, X., Wang, D., Qiao, L., Tao, W., et al. (2012). Low-frequency rTMS in refractory epilepsy. Epilepsia, 53(10), 1782–1789. https://doi.org/10.1111/j.1528-1167.2012.03626.x
Rossetti, A. O. (2012). Hypothermia in refractory status epilepticus. Critical Care, 16(Suppl 2), A26. https://doi.org/10.1186/cc11284
Yarım, G., & Kazak, F. (2015). Brain-derived neurotrophic factor. Atatürk University Veterinary Sciences Journal, 10(2), 120–129.
Bayrlee, A., Ganeshalingam, N., Kurczewski, L., & Brophy, G. M. (2015). Treatment of super-refractory status epilepticus. Current Neurology and Neuroscience Reports, 15(10), 66. https://doi.org/10.1007/s11910-015-0589-2
Legriel, S. (2019). Hypothermia as a treatment in status epilepticus. Epilepsy & Behavior, 101(Pt B), 106298. https://doi.org/10.1016/j.yebeh.2019.04.051
Zeiler, F. A., Matuszczak, M., Teitelbaum, J., Gillman, L. M., & Kazina, C. J. (2016). Electroconvulsive therapy for refractory status epilepticus. Seizure, 35, 23–32. https://doi.org/10.1016/j.seizure.2015.12.015
Trinka, E., & Brigo, F. (2019). Neurostimulation in refractory status epilepticus. Epilepsy & Behavior, 101(Pt B), 106551. https://doi.org/10.1016/j.yebeh.2019.106551
Ahmed, J., Metrick, M., Gilbert, A., Glasson, A., Singh, R., Ambrous, W., Brown, L., Aykroyd, L., & Bobel, K. (2018). Electroconvulsive therapy for super refractory status epilepticus. Journal of ECT, 34(1), e5–e9. https://doi.org/10.1097/YCT.0000000000000450
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
